

## INVITATION TO PRESENTATION OF CINCLUS PHARMA'S FOURTH QUARTER REPORT 2025

**Cinclus Pharma's fourth quarter report for October – December 2025 will be published on Wednesday, February 18, 2026, at 08:00 am CET. The company will host a live presentation the same day at 10:00 am CET.**

The report is presented by CEO Christer Ahlberg, Interim CFO Patrik Norgren and R&D Director Margit Mahlapuu. The presentation includes a Q&A session.

If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions.

<https://cinclus-pharma.events.inderes.com/q4-report-2025>

If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://events.inderes.com/cinclus-pharma/q4-report-2025/dial-in>

The report, the presentation and a recorded version of the presentation will also be available on the company's website: **Financial Reports | Cinclus Pharma**

**For additional information, please contact:**

---

Christer Ahlberg, CEO  
Phone: +46 70 675 33 30  
e-mail: [christer.ahlberg@cincluspharma.com](mailto:christer.ahlberg@cincluspharma.com)

Henrik Vikström, IR  
Phone: +46 70 952 80 06  
e-mail: [henrik.vikstrom@cincluspharma.com](mailto:henrik.vikstrom@cincluspharma.com)

## About Cinclus Pharma

---

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit [www.cincluspharma.com](http://www.cincluspharma.com).

## Attachments

---

**Invitation to presentation of Cinclus Pharma's fourth quarter report 2025**